查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1553567

肝炎治疗市场规模、份额、趋势分析报告：按疾病、通路、地区、细分市场预测，2024-2030

Hepatitis Therapeutics Market Size, Share & Trends Analysis Report By Disease (Hepatitis A, Hepatitis B, Hepatitis C), By Distribution Channel (Hospital Pharmacies), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格
简介目录

肝炎治疗市场的成长与趋势

Grand View Research, Inc.最新报告显示，到2030年，全球肝炎治疗市场规模预计将达到208.4亿美元，预测期内复合年增长率为3.7%。

预计在预测期内推动市场的因素包括肝炎感染数量增加、酒精和药物消费量增加以及肝炎治疗机会的增加。

根据患者患病时间的长短，病毒性肝炎通常分为两种。如果症状持续少于6个月，则归类为急性肝炎，如果症状持续超过6个月，则归类为慢性肝炎。 HIV 或 HCV 感染者的性伴侣、受感染血液的接受者、使用注射药物或鼻腔药物的患者以及生活在不卫生条件下的人群患肝炎的风险增加。

根据世界卫生组织的基本估计，全世界约有4亿人感染至少一种肝炎，每年约有1.4人死于肝炎。政府或私人机构积极进行疫苗接种以预防肝炎的情况很少。与甲型肝炎和乙型肝炎相比，HCV 会引起更严重的併发症。根据世界卫生组织估计，全世界每年有 1.5 亿人受到C型肝炎感染。此外，大多数感染HCV的人会发展为肝癌或肝硬化，近70万人死于C型肝炎感染及相关疾病。

肝炎治疗市场报告亮点

  • 到2023年，C型肝炎治疗将占据大部分市场占有率。
  • 2023年，由于意识层级高且拥有先进的医疗基础设施，北美地区占据了大部分收益占有率。
  • 然而，由于医疗保健支出迅速增加，亚太地区在预测期内的复合年增长率预计将达到 6.6%。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章肝炎治疗市场变数、趋势与范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 肝炎治疗市场分析工具
    • 波特的分析
    • PESTEL分析

第四章肝炎治疗市场：依疾病分类的估计与趋势分析

  • 细分仪表板
  • 肝炎治疗市场：2023 年和 2030 年疾病变化分析
  • 甲型肝炎
  • B型肝炎
  • C型肝炎
  • 其他的

第五章肝炎治疗市场：按分销管道估计和趋势分析

  • 细分仪表板
  • 肝炎治疗市场：2023 年和 2030 年分销管道波动分析
  • 医院药房
  • 药局和药房
  • 其他的

第六章 肝炎治疗市场：区域估计与趋势分析

  • 2023 年及 2030 年肝炎治疗市场占有率（按地区）
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 泰国
    • 韩国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • Teva Pharmaceutical Industries Ltd.
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche Ltd
    • Zydus Group
    • GSK plc.
    • AbbVie Inc.
    • Gilead Sciences, Inc.
    • Merck &Co., Inc.
    • Lupin
    • Cipla
简介目录
Product Code: GVR-1-68038-449-9

Hepatitis Therapeutics Market Growth & Trends:

The global hepatitis therapeutics market size is expected to reach USD 20.84 billion by 2030, registering a CAGR of 3.7% during the forecast period, according to a new report by Grand View Research, Inc. Few factors that are expected to drive the market over the forecast period include the rising number of hepatitis infected population, growing consumption of alcohol & drugs, and improving accessibility to hepatitis drugs.

Based on the duration for which the patient suffers, viral hepatitis is generally categorized into two types. If the condition lasts for less than six months, then it is classified as acute, when the condition persists for more than six months, then it is a case of chronic hepatitis. People with HIV infection & HCV-infected sexual partners, recipients of infected blood, patients who inject drugs & use intranasal drugs, and population groups who live in unhygienic conditions are at high risk of hepatitis.

Based on the estimates of WHO, approximately 400 million people are infected with at least one form of hepatitis globally, and annually nearly 1.4 people die due to the condition. In order to prevent hepatitis, few government and private agencies are actively involved in the vaccination drive to prevent hepatitis. As compared to hepatitis A and B, HCV leads to more serious complications. According to the estimates of WHO, globally annually 150 million are impacted by hepatitis C infection. Moreover, the majority of HCV infected patients develop liver cancer or liver cirrhosis and nearly 700,000 people die due to hepatitis C infection & associated conditions.

Hepatitis Therapeutics Market Report Highlights:

  • Owing to the high prevalence of target disease with subsequently surge in treatment rate HCV, thus hepatitis C therapeutics held the majority market share in 2023
  • In 2023, North American region accounted for the majority of the revenue share, owing to high patient awareness levels and the presence of advanced healthcare infrastructure
  • However, Asia Pacific is anticipated to witness the maximum growth with a CAGR of 6.6% over the forecast period owing to rapidly increasing healthcare expenditure.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Hepatitis Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Billion)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Hepatitis Therapeutics Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Hepatitis Therapeutics Market: Disease Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Hepatitis Therapeutics Market: Solution Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Hepatitis A
    • 4.3.1. Hepatitis A Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Hepatitis B
    • 4.4.1. Hepatitis B Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Hepatitis C
    • 4.5.1. Hepatitis C Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Others
    • 4.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Hepatitis Therapeutics Market: Distribution Channel Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Hepatitis Therapeutics Market: Distribution Channel Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Hospital Pharmacies
    • 5.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Drug Stores and Retail Pharmacies
    • 5.4.1. Drug Stores and Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Others
    • 5.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Hepatitis Therapeutics Market: Regional Estimates & Trend Analysis

  • 6.1. Hepatitis Therapeutics Market Share, By Region, 2023 & 2030 (USD Million)
  • 6.2. North America
    • 6.2.1. North America Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.2. U.S.
      • 6.2.2.1. U.S. Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.3. Canada
      • 6.2.3.1. Canada Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.4. Mexico
      • 6.2.4.1. Mexico Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3. Europe
    • 6.3.1. Europe Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.2. UK
      • 6.3.2.1. UK Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.3. Germany
      • 6.3.3.1. Germany Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.4. France
      • 6.3.4.1. France Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.5. Italy
      • 6.3.5.1. Italy Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.6. Spain
      • 6.3.6.1. Spain Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.7. Denmark
      • 6.3.7.1. Denmark Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.8. Sweden
      • 6.3.8.1. Sweden Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.9. Norway
      • 6.3.9.1. Norway Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. Japan
      • 6.4.2.1. Japan Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. China
      • 6.4.3.1. China Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. India
      • 6.4.4.1. India Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.5. Australia
      • 6.4.5.1. Australia Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.6. Thailand
      • 6.4.6.1. Thailand Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.7. South Korea
      • 6.4.7.1. South Korea Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Latin America
    • 6.5.1. Latin America Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. Brazil
      • 6.5.2.1. Brazil Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Argentina
      • 6.5.3.1. Argentina Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Middle East and Africa
    • 6.6.1. Middle East and Africa Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. South Africa
      • 6.6.2.1. South Africa Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. Saudi Arabia
      • 6.6.3.1. Saudi Arabia Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. UAE
      • 6.6.4.1. UAE Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. Kuwait
      • 6.6.5.1. Kuwait Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis by Key Market Participants
  • 7.2. Company Categorization
  • 7.3. Company Heat Map Analysis
  • 7.4. Company Profiles
    • 7.4.1. Teva Pharmaceutical Industries Ltd.
      • 7.4.1.1. Participant's Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Recent Developments/ Strategic Initiatives
    • 7.4.2. Bristol-Myers Squibb Company
      • 7.4.2.1. Participant's Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Recent Developments/ Strategic Initiatives
    • 7.4.3. F. Hoffmann-La Roche Ltd
      • 7.4.3.1. Participant's Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Recent Developments/ Strategic Initiatives
    • 7.4.4. Zydus Group
      • 7.4.4.1. Participant's Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Recent Developments/ Strategic Initiatives
    • 7.4.5. GSK plc.
      • 7.4.5.1. Participant's Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Recent Developments/ Strategic Initiatives
    • 7.4.6. AbbVie Inc.
      • 7.4.6.1. Participant's Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Recent Developments/ Strategic Initiatives
    • 7.4.7. Gilead Sciences, Inc.
      • 7.4.7.1. Participant's Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Recent Developments/ Strategic Initiatives
    • 7.4.8. Merck & Co., Inc.
      • 7.4.8.1. Participant's Overview
      • 7.4.8.2. Financial Performance
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Recent Developments/ Strategic Initiatives
    • 7.4.9. Lupin
      • 7.4.9.1. Participant's Overview
      • 7.4.9.2. Financial Performance
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Recent Developments/ Strategic Initiatives
    • 7.4.10. Cipla
      • 7.4.10.1. Participant's Overview
      • 7.4.10.2. Financial Performance
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Recent Developments/ Strategic Initiatives